A record level of 99% of Healthcare Professionals have provided named transparency on www.transfersofvalue.ie

Since July 2016, and in line with the IPHA Code of Practice for the Pharmaceutical Industry, companies have disclosed financial transfers of value (ToV)—whether direct or indirect, in cash or in kind—made to Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs). These disclosures are publicly accessible on www.transferofvalue.ie.

At 4pm today, June 30^th 2026, IPHA published the ToV Disclosure data for 2025.

• The total ToV amount for 2025 was €30,194,895 which is an 8% decrease compared to 2024 data (€32,832,186).
• The total ToV to HCPs increased by 8% to €6,146,746 for 2025 data (it was €5,683,314 for 2024 data) with 99% of HCPs named on the website! The proportion of named HCPs on the site has increased year on year since the website first went live in 2016.

Of the €6,146,746 total payments to HCPs, only 1.4% (i.e. €86,262) was paid to 36 un-named HCPs (in 2024, it was €178,169 to 74 un-named HCPs).

• The total ToV to HCOs was €8,317,095 which is a 6% decrease on the 2024 data value of €8,838,663. All HCO ToVs were disclosed individually thus achieving 100% HCO transparency again this year.
• The total figure for R&D investment in 2025 was €14,529,723, a significant 21% decrease in R&D investment on the 2024 data (€18,310,209).
• This is the first year that disclosure of Patient Organisation (“PO”) ToVs has been possible on www.transferofvalue.ie. There is a transitional period for companies, so that up to the end of June 2029 companies may choose to disclose their ToVs to POs on their own website OR on www.transferofvalue.ie. For all those that disclose on www.transferofvalue.ie the transition period is limited so that from the end of June 2029, at the latest, PO ToV data for 2028 and all subsequent years must appear on www.transferofvalue.ie. In 2025 the total ToV to POs that was disclosed on this site was €1,201,331.
• Also new for this year is that a summary table is available on the website (copied below) and that www.transferofvalue.ie is fully searchable by HCP or HCO name!

Currently, of the 50 companies who publish their data through the platform, 11 are non IPHA members with the remainder being IPHA member companies.

The shared ambition of our member companies is to bring innovative treatments to Irish patients under the guidance of qualified HCPs. We place great value on our longstanding, ethical relationships with doctors, nurses, dentists, and pharmacists, whose experience and insight are essential to advancing the development and appropriate use of new medicines.

To that end IPHA is committed to integrity and transparency in all interactions between our member companies and HCPs and HCOs. Our aim is to reach 100% named disclosure for HCPs, and we will continue to support our member companies in using legitimate interest as a legal basis for making these disclosures under data protection law.

ENDS

For any questions relating to Transfers of Value, please consult the FAQ section on the IPHA website at Transfers of Value – IPHA.